Stanford researchers have identified genetic variants carried by roughly one in ten people that significantly reduce the effectiveness of GLP-1 receptor agonists for blood sugar control.
New research from Stanford University has shed light on a puzzling clinical observation: why some patients see little benefit from blockbuster GLP-1 medications like semaglutide and tirzepatide. The study identified specific genetic variants that impair GLP-1 receptor signaling, affecting approximately 10 percent of the general population.
The phenomenon, which researchers are calling GLP-1 resistance, appears to diminish the ability of these drugs to regulate blood sugar in affected individuals. While the exact molecular mechanism is still under investigation, the finding has immediate clinical implications. Physicians prescribing GLP-1 agonists may eventually be able to use genetic screening to identify patients who are unlikely to respond well and steer them toward alternative therapies from the outset.
The discovery also raises questions about whether GLP-1 resistance affects weight-loss outcomes in addition to glycemic control, a question the research team plans to explore in follow-up studies. For the millions of patients currently taking or considering GLP-1 medications, the finding underscores the importance of personalized medicine approaches in metabolic disease treatment.
Source: Stanford Medicine
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.